EUCTR2014-004995-49-FR
进行中（未招募）
1 期
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed with Fabry Disease
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Fabry disease
- 发起方
- Genzyme Corporation
- 入组人数
- 11
- 状态
- 进行中（未招募）
- 最后更新
- 6年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Male patient with Fabry disease who previously completed study ACT13739\.
- •Patients, willing and able to provide signed informed consent.
- •Sexually active patients, willing to practice true abstinence in line with their preferred and usual lifestyle or using two acceptable effective methods of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 8
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- •Patients, in the opinion of the Investigator, unable to adhere to the requirements of the study.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients with Fabry DiseaseFabry diseaseMedDRA version: 18.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2014-004995-49-GBGenzyme Corporation11
进行中（未招募）
1 期
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients with Fabry DiseaseFabry diseaseMedDRA version: 18.0 Level: PT Classification code 10016016 Term: Fabry's disease System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2014-004995-49-PLGenzyme Corporation11
进行中（未招募）
1 期
Avalglucosidase Alfa Extension StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 20.0Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: PTClassification code 10053185Term: Glycogen storage disease type IISystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-003321-28-DKGenzyme Corporation21
进行中（未招募）
不适用
eoGAA Extension StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 18.0Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-003321-28-FRGenzyme Corporation18
进行中（未招募）
1 期
eoGAA Extension StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 20.0Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: PTClassification code 10053185Term: Glycogen storage disease type IISystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-003321-28-NLGenzyme Corporation21